Akebia Ther Stock Performance

AKBA Stock  USD 2.07  0.06  2.82%   
On a scale of 0 to 100, Akebia Ther holds a performance score of 6. The firm shows a Beta (market volatility) of 1.58, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Akebia Ther will likely underperform. Please check Akebia Ther's jensen alpha, maximum drawdown, and the relationship between the coefficient of variation and sortino ratio , to make a quick decision on whether Akebia Ther's price patterns will revert.

Risk-Adjusted Performance

OK

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Akebia Ther are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak fundamental drivers, Akebia Ther sustained solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
(2.82)
Five Day Return
(2.82)
Year To Date Return
8.95
Ten Year Return
(79.40)
All Time Return
(92.25)
JavaScript chart by amCharts 3.21.151234567891011Dec2025Feb -10-505101520
JavaScript chart by amCharts 3.21.15Akebia Ther Akebia Ther Dividend Benchmark Dow Jones Industrial
1
Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/18/2024
2
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
01/02/2025
3
Disposition of 20100 shares by Frieson Ron of Akebia Ther at 0.45 subject to Rule 16b-3
01/17/2025
4
Akebia Therapeutics Trading 10.9 percent Higher - Time to Buy - MarketBeat
01/24/2025
5
Acquisition by Ostrowski Erik of 292300 shares of Akebia Ther at 2.24 subject to Rule 16b-3
01/31/2025
6
Disposition of 55621 shares by Nicholas Grund of Akebia Ther at 2.1 subject to Rule 16b-3
02/03/2025
7
Akebia Therapeutics Reports Inducement Grants UnderNasdaq Listi
02/04/2025
8
Akebia Therapeutics, Inc. SVP Steven Keith Burke Sells 50,506 Shares
02/05/2025
9
10.7 Billion Healthcare Mobile Robots Market Outlook, 2030 by Type, End Use and Region - Akebia Therapeutics, ABB, Aethon, Omron Corp., and Amazon Lead the Comp...
02/07/2025
10
Akebia Therapeutics Raised to Hold at StockNews.com - MarketBeat
02/11/2025
11
Chris Rombach appointed President of Asahi Kasei Bioprocess America
02/18/2025
Begin Period Cash Flow93.2 M
  

Akebia Ther Relative Risk vs. Return Landscape

If you would invest  182.00  in Akebia Ther on November 21, 2024 and sell it today you would earn a total of  25.00  from holding Akebia Ther or generate 13.74% return on investment over 90 days. Akebia Ther is currently generating 0.2758% in daily expected returns and assumes 3.3496% risk (volatility on return distribution) over the 90 days horizon. In different words, 29% of stocks are less volatile than Akebia, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
JavaScript chart by amCharts 3.21.15CashMarketAKBA 0.00.51.01.52.02.53.03.5 -0.050.000.050.100.150.200.250.30
       Risk  
Given the investment horizon of 90 days Akebia Ther is expected to generate 4.68 times more return on investment than the market. However, the company is 4.68 times more volatile than its market benchmark. It trades about 0.08 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.04 per unit of risk.

Akebia Ther Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Akebia Ther's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Akebia Ther, and traders can use it to determine the average amount a Akebia Ther's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0823

Best PortfolioBest Equity
Good Returns
Average Returns
Small ReturnsAKBA
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative Returns

Estimated Market Risk

 3.35
  actual daily
29
71% of assets are more volatile

Expected Return

 0.28
  actual daily
5
95% of assets have higher returns

Risk-Adjusted Return

 0.08
  actual daily
6
94% of assets perform better
Based on monthly moving average Akebia Ther is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Akebia Ther by adding it to a well-diversified portfolio.

Akebia Ther Fundamentals Growth

Akebia Stock prices reflect investors' perceptions of the future prospects and financial health of Akebia Ther, and Akebia Ther fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Akebia Stock performance.
Return On Equity-5.53
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-400%-300%-200%-100%
Return On Asset-0.0937
Profit Margin(0.27) %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Operating Margin(0.33) %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Current Valuation479.29 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%150%
Shares Outstanding218.18 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%2,000%
Price To Earning(4.84) X
Price To Book4.12 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-120%-100%-80%-60%-40%-20%
Price To Sales2.66 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Revenue194.62 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%10,000%20,000%30,000%40,000%
Gross Profit142.93 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-1,000%-800%-600%-400%-200%0%200%400%
EBITDA(8.27 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%1,000%2,000%3,000%4,000%
Net Income(51.92 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-311,000%2,000%3,000%4,000%
Cash And Equivalents143.89 M
Cash Per Share0.78 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-311,000%2,000%3,000%4,000%
Total Debt104.18 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31200,000%400,000%600,000%800,000%1,000,000%1,200,000%
Debt To Equity2.15 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-500,000%0%500,000%1,000,000%1,500,000%2,000,000%2,500,000%
Current Ratio1.30 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%2,000%2,500%3,000%3,500%
Book Value Per Share(0.24) X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-2,500%-2,000%-1,500%-1,000%-500%
Cash Flow From Operations(23.38 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-1,000%0%1,000%2,000%3,000%
Earnings Per Share(0.22) X
Market Capitalization451.63 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%150%
Total Asset241.7 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3110,000%20,000%30,000%40,000%
Retained Earnings(1.61 B)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%2,000%2,500%
Working Capital18.28 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Current Asset141.02 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-315,000%10,000%15,000%20,000%
Current Liabilities11.87 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%1,000%2,000%3,000%4,000%5,000%

About Akebia Ther Performance

By analyzing Akebia Ther's fundamental ratios, stakeholders can gain valuable insights into Akebia Ther's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Akebia Ther has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Akebia Ther has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 88.83  84.38 
Return On Tangible Assets(0.32)(0.33)
Return On Capital Employed(0.38)(0.39)
Return On Assets(0.19)(0.20)
Return On Equity 1.95  2.05 

Things to note about Akebia Ther performance evaluation

Checking the ongoing alerts about Akebia Ther for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Akebia Ther help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Akebia Ther had very high historical volatility over the last 90 days
Akebia Ther has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 194.62 M. Net Loss for the year was (51.92 M) with profit before overhead, payroll, taxes, and interest of 142.93 M.
Akebia Ther currently holds about 143.89 M in cash with (23.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.78.
Latest headline from finance.yahoo.com: Chris Rombach appointed President of Asahi Kasei Bioprocess America
Evaluating Akebia Ther's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Akebia Ther's stock performance include:
  • Analyzing Akebia Ther's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Akebia Ther's stock is overvalued or undervalued compared to its peers.
  • Examining Akebia Ther's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Akebia Ther's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Akebia Ther's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Akebia Ther's stock. These opinions can provide insight into Akebia Ther's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Akebia Ther's stock performance is not an exact science, and many factors can impact Akebia Ther's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Akebia Stock analysis

When running Akebia Ther's price analysis, check to measure Akebia Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akebia Ther is operating at the current time. Most of Akebia Ther's value examination focuses on studying past and present price action to predict the probability of Akebia Ther's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akebia Ther's price. Additionally, you may evaluate how the addition of Akebia Ther to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
FinTech Suite
Use AI to screen and filter profitable investment opportunities